Millendo Therapeutics, Inc. (MLND)
|Net Income (ttm)||-41.74M|
|Trading Day||January 22|
|Day's Range||1.88 - 1.95|
|52-Week Range||1.40 - 9.58|
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces operating and financial results for the quarter ended September 30, 2020.
There are some investors who buy stocks that are trading below their liquidation value because they believe they can achieve impressive gains from their investments after the market has reasse...
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine disease...
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Participate in September Investor Conferences
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Investors need to pay close attention to Millendo (MLND) stock based on the movements in the options market lately.
As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.
Millendo Therapeutics: A Forgotten Biotech With Strong Potential
Millendo Therapeutics Inc’s (NASDAQ: MLND) lead asset livoletide is in a registrational study (ZEPHYR) for the treatment of PraderWilli Syndrome (PWS), which is an unmet need, according to Wed...
It’s not that unusual in the world of biotech and emerging medtech to run across companies that have previously never been heard of or covered.
Millendo Therapeutics, a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
|Stock Exchange |
|Ticker Symbol |
According to 3 analysts, the average rating for MLND stock is "Hold." The 12-month stock price forecast is 2.00, which is an increase of 3.09% from the latest price.